The FASEB Journal, Vol 9, 428-433, Copyright © 1995 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Recombinant glycosylasparaginase and in vitro correction of aspartylglycosaminuria

I Mononen, N Heisterkamp, U Dunder, EL Romppanen, T Noronkoski, I Kuronen and J Groffen
Department of Clinical Chemistry, Kuopio University Hospital, Finland.

Aspartylglycosaminuria (AGU) is the most common disorder of glycoprotein degradation. AGU patients are deficient in glycosylasparaginase (GA), which results in accumulation of aspartylglucosamine in body fluids and tissues. Human glycosylasparaginase was stably overexpressed in NIH-3T3 mouse fibroblasts, in which the unusual posttranslational processing and maturation of the enzyme occurred in a high degree. The recombinant enzyme was isolated as two isoforms, which were both phosphorylated, and actively transported into AGU fibroblasts and lymphoblasts through mannose-6-phosphate receptor-mediated endocytosis. The rate of uptake into fibroblasts was half-maximal when the concentration of GA in the medium was 5 x 10(-8) M. Immunofluorescence microscopy suggested compartmentalization of the recombinant enzyme in the lysosomes. Supplementation of culture medium with either isoform cleared AGU lymphoblasts of stored aspartylglucosamine when glycosylasparaginase activity in the cells reached 3-4% of that in normal lymphoblasts. A relatively small amount of recombinant GA in the culture medium was sufficient to reverse pathology in the target cells, indicating high corrective quality of the enzyme preparations. The combined evidence indicates that enzyme replacement therapy with the present recombinant glycosylasparaginase might reverse pathology at least in somatic cells of AGU patients.

This article has been cited by other articles:

				E. Kelo, U. Dunder, and I. Mononen Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy Glycobiology, January 1, 2005; 15(1): 79 - 85. [Abstract] [Full Text] [PDF]

				U. DUNDER, V. KAARTINEN, P. VALTONEN, E. VÄÄNÄNEN, V.-M. KOSMA, N. HEISTERKAMP, J. GROFFEN, and I. MONONEN Enzyme replacement therapy in a mouse model of aspartylglycosaminuria FASEB J, February 1, 2000; 14(2): 361 - 367. [Abstract] [Full Text]

				P. K. Ylikangas and I. T. Mononen Glycosylasparaginase as a Marker Enzyme in the Detection of I-Cell Disease Clin. Chem., December 1, 1998; 44(12): 2543 - 2544. [Full Text] [PDF]

				T. Noronkoski, I. B. Stoineva, I. P. Ivanov, D. D. Petkov, and I. Mononen Glycosylasparaginase-catalyzed Synthesis and Hydrolysis of beta -Aspartyl Peptides J. Biol. Chem., October 9, 1998; 273(41): 26295 - 26297. [Abstract] [Full Text] [PDF]

				H.-C. Guo, Q. Xu, D. Buckley, and C. Guan Crystal Structures of Flavobacterium Glycosylasparaginase. AN N-TERMINAL NUCLEOPHILE HYDROLASE ACTIVATED BY INTRAMOLECULAR PROTEOLYSIS J. Biol. Chem., August 7, 1998; 273(32): 20205 - 20212. [Abstract] [Full Text] [PDF]